269 related articles for article (PubMed ID: 34797200)
21. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
[TBL] [Abstract][Full Text] [Related]
22. Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.
White C; Scott RJ; Paul C; Ziolkowski A; Mossman D; Fox SB; Michael M; Ackland S
Clin Pharmacol Ther; 2022 Oct; 112(4):791-802. PubMed ID: 35607723
[TBL] [Abstract][Full Text] [Related]
23. Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing-The experience of a large oncology center in the United Kingdom.
Wang L; Howlett S; Essapen S
Semin Oncol; 2022 Apr; 49(2):170-177. PubMed ID: 35027218
[TBL] [Abstract][Full Text] [Related]
24. Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
Stavraka C; Pouptsis A; Okonta L; DeSouza K; Charlton P; Kapiris M; Marinaki A; Karapanagiotou E; Papadatos-Pastos D; Mansi J
Breast Cancer Res Treat; 2019 Jun; 175(2):511-517. PubMed ID: 30746637
[TBL] [Abstract][Full Text] [Related]
25. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
Etienne-Grimaldi MC; Pallet N; Boige V; Ciccolini J; Chouchana L; Barin-Le Guellec C; Zaanan A; Narjoz C; Taieb J; Thomas F; Loriot MA;
Eur J Cancer; 2023 Mar; 181():3-17. PubMed ID: 36621118
[TBL] [Abstract][Full Text] [Related]
26. Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?
Arrivé C; Fonrose X; Thomas F; Roth G; Jacquet E; Brice A; Chirica C; Farneti D; Frenoux C; Stanke-Labesque F; Gautier-Veyret E
Br J Clin Pharmacol; 2023 Aug; 89(8):2446-2457. PubMed ID: 36918744
[TBL] [Abstract][Full Text] [Related]
27. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.
Henricks LM; Lunenburg CA; Meulendijks D; Gelderblom H; Cats A; Swen JJ; Schellens JH; Guchelaar HJ
Pharmacogenomics; 2015; 16(11):1277-86. PubMed ID: 26265346
[TBL] [Abstract][Full Text] [Related]
28. A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.
De Falco V; Natalicchio MI; Napolitano S; Coppola N; Conzo G; Martinelli E; Zanaletti N; Vitale P; Giunta EF; Vietri MT; Vitiello PP; Ciardiello D; Marinaccio A; De Vita F; Ciardiello F; Troiani T
Medicine (Baltimore); 2019 May; 98(21):e15759. PubMed ID: 31124962
[TBL] [Abstract][Full Text] [Related]
29. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.
Pallet N; Hamdane S; Garinet S; Blons H; Zaanan A; Paillaud E; Taieb J; Laprevote O; Loriot MA; Narjoz C
Br J Cancer; 2020 Sep; 123(5):811-818. PubMed ID: 32595208
[TBL] [Abstract][Full Text] [Related]
30. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
Saif MW
Cancer Genomics Proteomics; 2013; 10(2):89-92. PubMed ID: 23603345
[TBL] [Abstract][Full Text] [Related]
31. Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.
de With M; Knikman J; de Man FM; Lunenburg CATC; Henricks LM; van Kuilenburg ABP; Maring JG; van Staveren MC; de Vries N; Rosing H; Beijnen JH; Pluim D; Modak A; Imholz ALT; van Schaik RHN; Schellens JHM; Gelderblom H; Cats A; Guchelaar HJ; Mathijssen RHJ; Swen JJ; Meulendijks D
Clin Pharmacol Ther; 2022 Jul; 112(1):62-68. PubMed ID: 35397172
[TBL] [Abstract][Full Text] [Related]
32. Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
Kanai M; Kawaguchi T; Kotaka M; Manaka D; Hasegawa J; Takagane A; Munemoto Y; Kato T; Eto T; Touyama T; Matsui T; Shinozaki K; Matsumoto S; Mizushima T; Mori M; Sakamoto J; Ohtsu A; Yoshino T; Saji S; Matsuda F
Cancer Med; 2023 Apr; 12(7):7808-7814. PubMed ID: 36524458
[TBL] [Abstract][Full Text] [Related]
33. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Meulendijks D; Cats A; Beijnen JH; Schellens JH
Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
[TBL] [Abstract][Full Text] [Related]
34. A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report.
Malekkou A; Tomazou M; Mavrikiou G; Dionysiou M; Georgiou T; Papaevripidou I; Alexandrou A; Sismani C; Drousiotou A; Grafakou O; Petrou PP
BMC Med Genomics; 2024 Mar; 17(1):78. PubMed ID: 38528593
[TBL] [Abstract][Full Text] [Related]
35. Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
De Luca O; Salerno G; De Bernardini D; Torre MS; Simmaco M; Lionetto L; Gentile G; Borro M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430399
[TBL] [Abstract][Full Text] [Related]
36. Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience.
Jolivet C; Nassabein R; Soulières D; Weng X; Amireault C; Ayoub JP; Beauregard P; Blais N; Carrier C; Cloutier AS; Desnoyers A; Lemay AS; Lemay F; Loungnarath R; Jolivet J; Letendre F; Tehfé M; Vadnais C; Viens D; Aubin F
Oncologist; 2021 Apr; 26(4):e597-e602. PubMed ID: 33274825
[TBL] [Abstract][Full Text] [Related]
37. DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.
Paulsen NH; Vojdeman F; Andersen SE; Bergmann TK; Ewertz M; Plomgaard P; Hansen MR; Esbech PS; Pfeiffer P; Qvortrup C; Damkier P
Basic Clin Pharmacol Toxicol; 2022 Nov; 131(5):325-346. PubMed ID: 35997509
[TBL] [Abstract][Full Text] [Related]
38. Unveiling Discrepant and Rare Dihydropyrimidine Dehydrogenase (DPYD) Results Using an In-House Genotyping Test: A Case Series.
Nguyen DG; Morris SA; Chen A; Moore DC; Hanson SL; Larck C; Musselwhite LW; Turner JD; Salem ME; Kwange SO; Hamilton A; Steuerwald N; Patel JN
J Natl Compr Canc Netw; 2024 May; 22(4):. PubMed ID: 38754463
[TBL] [Abstract][Full Text] [Related]
39. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
Caudle KE; Thorn CF; Klein TE; Swen JJ; McLeod HL; Diasio RB; Schwab M
Clin Pharmacol Ther; 2013 Dec; 94(6):640-5. PubMed ID: 23988873
[TBL] [Abstract][Full Text] [Related]
40. Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study.
Kleinjan JP; Brinkman I; Bakema R; van Zanden JJ; van Rooijen JM
Anticancer Drugs; 2019 Apr; 30(4):410-415. PubMed ID: 30628914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
